Earl F. Kimble
Ligand Pharmaceuticals (United States)(US)
Publications by Year
Research Areas
Inflammatory mediators and NSAID effects, Cytokine Signaling Pathways and Interactions, Synthesis and Reactions of Organic Compounds, Estrogen and related hormone effects, Synthesis of heterocyclic compounds
Most-Cited Works
- → Preclinical pharmacology of lumiracoxib: a novel selective inhibitor of cyclooxygenase‐2(2005)123 cited
- → Preclinical pharmacology of robenacoxib: a novel selective inhibitor of cyclooxygenase‐2(2009)77 cited
- → Selective functional inhibition of JAK‐3 is sufficient for efficacy in collagen‐induced arthritis in mice(2010)74 cited
- → Novel C5a Receptor Antagonists Regulate Neutrophil Functions In Vitro and In Vivo(1998)59 cited
- → The effects of diclofenac sodium on arachidonic acid metabolism(1985)55 cited
- → Substituted chromenes as potent, orally active 5-lipoxygenase inhibitors(1993)34 cited
- → Derivatives of 2-[[N-(Aminocarbonyl)-N-hydroxyamino]methyl]-1,4-benzodioxan as Orally Active 5-Lipoxygenase Inhibitors(1995)31 cited
- → Characterization of CGS 8515 as a selective 5-lipoxygenase inhibitor using in vitro and in vivo models(1988)25 cited
- → Novel Pyrrolidine Ureas as C−C Chemokine Receptor 1 (CCR1) Antagonists(2009)24 cited
- → 2-Benzimidazolyl-9-(chroman-4-yl)-purinone derivatives as JAK3 inhibitors(2009)18 cited